{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:31:01Z","timestamp":1774085461387,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuroradiology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00234-016-1769-8","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T09:12:16Z","timestamp":1483953136000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma"],"prefix":"10.1007","volume":"59","author":[{"given":"Lei","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Stroiney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinrong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Helgager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,9]]},"reference":[{"key":"1769_CR1","unstructured":"DeAngelis L.M, Wen PY (2012) Primary and metastatic tumors of the nervous system. In: Longo D.L. FAS, Kasper D.L., Hauser S.L., Jameson J, Loscalzo J (eds.) Harrison\u2019s principles of internal medicine"},{"key":"1769_CR2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2217\/imt.11.39","volume":"3","author":"T Avril","year":"2011","unstructured":"Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V (2011) Mechanisms of immunomodulation in human glioblastoma. Immunotherapy 3:42\u201344","journal-title":"Immunotherapy"},{"key":"1769_CR3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122\u2013133","journal-title":"N Engl J Med"},{"key":"1769_CR4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319","journal-title":"N Engl J Med"},{"key":"1769_CR5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2016","unstructured":"Reardon DA, Gokhale PC, Klein SR et al (2016) Glioblastomaeradication following immune checkpoint blockade in an orthotopic, Immunocompetentmodel. Cancer Immunol Res 4:124\u2013135","journal-title":"Cancer Immunol Res"},{"key":"1769_CR6","first-page":"343","volume":"86","author":"J Zeng","year":"2013","unstructured":"Zeng J, See AP, Phallen J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J RadiatOncolBiolPhys 86:343\u2013349","journal-title":"Int J RadiatOncolBiolPhys"},{"key":"1769_CR7","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","volume":"20","author":"DA Wainwright","year":"2014","unstructured":"Wainwright DA, Chang AL, Dey M et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 20:5290\u20135301","journal-title":"Clin Cancer Res"},{"issue":"Suppl 7","key":"1769_CR8","doi-asserted-by":"crossref","first-page":"vii24","DOI":"10.1093\/neuonc\/nou286","volume":"16","author":"DA Reardon","year":"2014","unstructured":"Reardon DA, Ballman KV, Buckner JC, Chang SM, Ellingson BM (2014) Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro-Oncology 16(Suppl 7):vii24\u2013vii35","journal-title":"Neuro-Oncology"},{"key":"1769_CR9","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. The Lancet Oncology 16:e534\u2013e542","journal-title":"The Lancet Oncology"},{"key":"1769_CR10","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"1769_CR11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1148\/radiol.13122024","volume":"269","author":"HH Chu","year":"2013","unstructured":"Chu HH, Choi SH, Ryoo I et al (2013) Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Radiology 269:831\u2013840","journal-title":"Radiology"},{"key":"1769_CR12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00234-010-0802-6","volume":"53","author":"M Vrabec","year":"2011","unstructured":"Vrabec M, Van Cauter S, Himmelreich U et al (2011) MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology 53:721\u2013731","journal-title":"Neuroradiology"},{"key":"1769_CR13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3174\/ajnr.A2479","volume":"32","author":"A Gupta","year":"2011","unstructured":"Gupta A, Young RJ, Karimi S et al (2011) Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiology 32:1301\u20131306","journal-title":"AJNR Am J Neuroradiology"},{"key":"1769_CR14","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1158\/1078-0432.CCR-11-0625","volume":"18","author":"MJ Wieduwilt","year":"2012","unstructured":"Wieduwilt MJ, Valles F, Issa S et al (2012) Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 18:1146\u20131155","journal-title":"Clin Cancer Res"},{"key":"1769_CR15","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J ClinOncol 28:1963\u20131972","journal-title":"J ClinOncol"},{"key":"1769_CR16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/radiol.13131305","volume":"271","author":"BM Ellingson","year":"2014","unstructured":"Ellingson BM, Kim HJ, Woodworth DC et al (2014) Recurrentglioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271:200\u2013210","journal-title":"Radiology"},{"key":"1769_CR17","first-page":"302","volume":"17","author":"L Porto","year":"2013","unstructured":"Porto L, Jurcoane A, Schwabe D, Kieslich M, Hattingen E (2013) Differentiation between high and low grade tumours in paediatric patients by using apparent diffusion coefficients. Eur J PaediatrNeurol 17:302\u2013307","journal-title":"Eur J PaediatrNeurol"},{"key":"1769_CR18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3174\/ajnr.A3757","volume":"35","author":"SF Kralik","year":"2014","unstructured":"Kralik SF, Taha A, Kamer AP, Cardinal JS, Seltman TA, Ho CY (2014) Diffusion imaging for tumor grading of supratentorial brain tumors in the first year of life. AJNR Am J Neuroradiol 35:815\u2013823","journal-title":"AJNR Am J Neuroradiol"},{"key":"1769_CR19","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/neuonc\/nou142","volume":"16","author":"PS LaViolette","year":"2014","unstructured":"LaViolette PS, Mickevicius NJ, Cochran EJ et al (2014) Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro-Oncology 16:1599\u20131606","journal-title":"Neuro-Oncology"},{"key":"1769_CR20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1148\/radiology.217.2.r00nv36377","volume":"217","author":"AJ Kumar","year":"2000","unstructured":"Kumar AJ, Leeds NE, Fuller GN et al (2000) Malignantgliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377\u2013384","journal-title":"Radiology"},{"key":"1769_CR21","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1212\/01.wnl.0000242894.21705.3c","volume":"67","author":"S Ulmer","year":"2006","unstructured":"Ulmer S, Braga TA, Barker FG 2nd, Lev MH, Gonzalez RG, Henson JW (2006) Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 67:1668\u20131670","journal-title":"Neurology"},{"key":"1769_CR22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/ern.13.7","volume":"13","author":"TJ Kruser","year":"2013","unstructured":"Kruser TJ, Mehta MP, Robins HI (2013) Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurother 13:389\u2013403","journal-title":"Expert Rev Neurother"},{"key":"1769_CR23","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3174\/ajnr.A2397","volume":"32","author":"LC Hygino da Cruz","year":"2011","unstructured":"Hygino da Cruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of Posttreatmentglioma. Am J Neuroradiol 32:1978\u20131985","journal-title":"Am J Neuroradiol"},{"key":"1769_CR24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2015","unstructured":"Reardon DA, Gokhale PC, Klein SR et al (2015) Glioblastomaeradication following immune checkpoint blockade in an orthotopic, Immunocompetentmodel. Cancer Immunol Res 4:124\u2013135","journal-title":"Cancer Immunol Res"},{"key":"1769_CR25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3174\/ajnr.A3837","volume":"35","author":"A Hilario","year":"2014","unstructured":"Hilario A, Sepulveda JM, Perez-Nunez A et al (2014) A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas. AJNR Am J Neuroradiol 35:1096\u20131102","journal-title":"AJNR Am J Neuroradiol"},{"key":"1769_CR26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3174\/ajnr.A4218","volume":"36","author":"AJ Prager","year":"2015","unstructured":"Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ (2015) Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 36:877\u2013885","journal-title":"AJNR Am J Neuroradiol"},{"key":"1769_CR27","first-page":"16","volume":"19","author":"M Nagane","year":"2014","unstructured":"Nagane M, Kobayashi K, Tanaka M et al (2014) Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. Int J ClinOncol 19:16\u201323","journal-title":"Int J ClinOncol"},{"key":"1769_CR28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11060-013-1225-0","volume":"115","author":"C Chen","year":"2013","unstructured":"Chen C, Huang R, MacLean A et al (2013) Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neuro-Oncol 115:267\u2013276","journal-title":"J Neuro-Oncol"},{"key":"1769_CR29","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3174\/ajnr.A3053","volume":"33","author":"S Mong","year":"2012","unstructured":"Mong S, Ellingson BM, Nghiemphu PL et al (2012) Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 33:1763\u20131770","journal-title":"AJNR Am J Neuroradiol"},{"key":"1769_CR30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ejrad.2009.01.013","volume":"73","author":"F Yamasaki","year":"2010","unstructured":"Yamasaki F, Sugiyama K, Ohtaki M et al (2010) Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging. Eur J Radiol 73:532\u2013537","journal-title":"Eur J Radiol"},{"key":"1769_CR31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1148\/radiol.2353031338","volume":"235","author":"F Yamasaki","year":"2005","unstructured":"Yamasaki F, Kurisu K, Satoh K et al (2005) Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 235:985\u2013991","journal-title":"Radiology"},{"key":"1769_CR32","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1200\/JCO.1994.12.9.1886","volume":"12","author":"CJ Watling","year":"1994","unstructured":"Watling CJ, Lee DH, Macdonald DR, Cairncross JG (1994) Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J ClinOncol 12:1886\u20131889","journal-title":"J ClinOncol"},{"key":"1769_CR33","first-page":"1226","volume":"16","author":"JJ Goh","year":"2009","unstructured":"Goh JJ, See SJ, Ang E, Ng WH (2009) Vanishing glioblastoma after corticosteroid therapy. J ClinNeurosci 16:1226\u20131228","journal-title":"J ClinNeurosci"},{"key":"1769_CR34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11060-015-1743-z","volume":"122","author":"A Elson","year":"2015","unstructured":"Elson A, Bovi J, Siker M, Schultz C, Paulson E (2015) Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2\/FLAIR volume as adverse prognostic indicators in glioblastoma. J Neuro-Oncol 122:549\u2013558","journal-title":"J Neuro-Oncol"}],"container-title":["Neuroradiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00234-016-1769-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00234-016-1769-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00234-016-1769-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T08:37:40Z","timestamp":1568709460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00234-016-1769-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,9]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s00234-016-1769-8","relation":{},"ISSN":["0028-3940","1432-1920"],"issn-type":[{"value":"0028-3940","type":"print"},{"value":"1432-1920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,9]]}}}